0.05Open0.20Pre Close16 Volume920 Open Interest62.50Strike Price104.00Turnover168.23%IV32.69%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type0.0544Delta0.0141Gamma277.82Leverage Ratio-0.1036Theta0.0002Rho15.13Eff Leverage0.0051Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
No comment yet